undamentalytics Newsletter
Sign in

Lyell Immunopharma, Inc. cash flow statement

In fiscal 2025, Lyell Immunopharma, Inc.'s operations generated −$150m of cash; it spent $780,000 on capital projects, leaving free cash flow of −$151m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations39−161−126−170−164−162−150−133
Depreciation and amortisation14141820201210
Stock-based pay1633628247334240
Capital spending165166243011
Free cash flow23−212−192−194−166−163−151−134
Free cash flow after stock pay8−246−254−276−213−196−193−174
Share buybacks01200————
Shares issued————0050—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: AIM vs LYELIBIO vs LYELLSTA vs LYEL

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Lyell Immunopharma, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lyell Immunopharma, Inc.